NEFL and adrenomyeloneuropathy: To elucidate whether NfL could be used as a quantitative outcome measure also for onset and progression of the non-inflammatory milder X-ALD variant, we compared the amount of NfL with the severity of the myelopathy in individual AMN patients as determined by the EDSS.